• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Resilience Acquires Ology Bioservices

    RDIF, Hualan Ink COVID-19 Vaccine Deal

    Kintor, Visum Enter COVID-19 Manufacturing Partnership

    Pfizer, BioNTech Expand COVID-19 Vaccine Agreement with EU

    Evotec Enters Master Service Agreement with Kazia Therapeutics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Resilience Acquires Ology Bioservices

    RDIF, Hualan Ink COVID-19 Vaccine Deal

    Pfizer, BioNTech Expand COVID-19 Vaccine Agreement with EU

    Evotec Enters Master Service Agreement with Kazia Therapeutics

    Bristol Myers Squibb Expands at Cambridge Crossing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Emergent BioSolutions

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Adare Pharma Solutions

    PCI Pharma Services

    Baxter BioPharma Solutions

    Quotient Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Exploring Potential Benefits of Outcomes-Based Contracts

    Achieving a successful transition, the benefits, potential downside, and looking forward

    Related CONTENT
    • Pharma Manufacturing: Methods for Real-Time Microbiology
    • Catalent, Acura Enter Clinical Manufacturing Pact
    • Leveraging Machine Learning and AI in Clinical Research
    • Growth in Biologics and Maintaining Patient Satisfaction
    • Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved
    Dean Erhardt, President and CEO, D2 Consulting 09.25.19
    As policymakers and payers continue to make the shift from fee-for-service toward value-based approaches, it’s clear that hold-outs against this trend will have the most to lose in terms of missed opportunity.  

    Value-based purchasing encourages providers to participate in risk-bearing arrangements and implement programs that base Medicare reimbursement on patient clinical outcomes measures, such as hospital readmission rates. Similarly, private payers have implemented performance-based incentive programs and risk-sharing arrangements for hospitals and physicians.

    Adopting value-based strategies requires adaptability, knowledge of strategies and, in most cases, guidance when it comes to for successful negotiations that respond to changes resulting from regulatory and market pressures. The overall goal is to reduce cost without compromising safety and quality. 
     
    Achieving a Successful Transition
    The key to success lies in optimizing a strategy to show the value of a product to each health plan/payer in a way that sidesteps risk and drives optimal reimbursement. Therefore, it’s important to understand the impact of bundled payments, accountable care, comparative effectiveness research (CER), evidence-based medicine (EBM) and payments linked to performance. Complex regulatory issues must also be addressed in order to successfully negotiate value-based payment models.
     
    Stakeholders should seek a commercial services partner with expertise in the legal and business details surrounding commercial or government arrangements for payers. The right partners can also guide manufacturers on how to demonstrate flexibility and communicate their understanding and appreciation of stakeholder expectations.
     
    Value-based contracting represents an opportunity but stakeholders must first seek the knowledge, expertise and experience they need to achieve measurable results.
     
    The Benefits ofOutcomes-Based Contracts
    High drug prices have sparked increased interest in outcomes-based contracts, which tie rebates and discounts for expensive pharmaceutical products to the outcomes observed in the patients and make it possible for insurers and health care systems to improve value. Under these contracts, purchasers pay more for a drug when it effectively leads to improved outcomes and less when it falls short of expectations.

    Under an outcomes-based contract between a pharmaceutical manufacturer and a payer, reimbursement for a drug is based in part on outcomes of the drug’s use in a patient population. Instead of the payer covering all prescriptions at a single price, the initial price remains if a specified percentage of patients achieves the determined outcome. Conversely, if the outcome goal is not met, the manufacturer refunds some of the original price to the payer.
    Payers are able to prevent wasted resources on expensive drugs that fail to translate in the real world.

    Pharmaceutical manufacturers and purchasers have an opportunityto provide an alternative option to closed formularies, in which drugs can remain on the formularies in exchange for outcomes guarantees. In such cases, manufacturers retain sales volume and purchasers share the risk of low-value spending with manufacturers. This can lead to increased coverage of medicines for patients. 

    Potential Downside
    Keep in mind thatoutcomes-based contracts don’t apply to most drugs in the near term because of outcomes measurement limitations, and electronic health records and lab values that remain difficult to access for analysis.

    Some payersstate they have negotiated meaningful rebate differences in outcomes-based contracts—creating the potential for real savings. On the other hand, some payers state that the rebates they would receive for unmet outcomes would fail to offset the increase in costs associated with collecting and analyzing the data. Because brand-name pharmaceutical manufacturers set the price of their drugs under market conditions, they can raise a drug’s initial price to account for the possibility of an outcomes-based rebate.

    Despite rebate levels, contracts would not affect patient out-of-pocket costs. Patient costs occur at the point of sale, while the contracts provide retrospective rebates from manufacturers to the payers that might be calculated months after the prescription is filled. As outcomes-based contracts build momentum, it will be important to consider potential ways to allow patients to share in the savings.

    Outcomes-based pharmaceutical contracts could potentially move spending toward more effective treatments, but they are not likely to lower spending on a broad scale, given the limits on their applicability and meaningful metrics. The contracts apply only to a limited subset of drugs and are mostly linked to measures that do not directly reflect patient health outcomes.

    Looking Forward
    It’s possible that Medicare or Medicaid would consider outcomes-based pharmaceutical contracts, especially if tested in arrangements through the Center for Medicare and Medicaid Innovation. For now, political backlash against outcomes-based contracts remains staunch. Going forward, possible outcomes-based contracts tested under Medicare Part D should be independent of other potential changes in pharmaceutical reimbursement, such as direct pricing reform.

    In the case of contracts between manufacturers and health plans that include private plans administering Medicaid and Medicare, price and health outcomes data would need to be kept confidential but rigorously and independently analyzed. Also, an outcomes-based contracting pilot would have to be voluntary until more public information on its implications becomes available.

    Inevitably, as interest in value or outcomes-based pharmaceutical contracts grows, questions will revolve around their ability to effectively improve quality or generate true savings. Testing outcomes-based contracts in Medicare and Medicaid populations could serve as the first significant step toward determining whether the contracts can create real improvements in the value of pharmaceutical care.



     
    Dean Erhardt offers over 20 years of strategic marketing and management experience across both the consumer product and pharmaceutical arenas.  His areas of expertise include analysis and development of pharmaceutical support programs, pharmaceutical and consumer product distribution, and specialty pharmaceutical product management.  Mr. Erhardt’s experience has spanned several Fortune 500 organizations including Express Scripts, Cardinal Health and U.S. Healthcare. Currently, Mr. Erhardt supports companies in the launching and reimbursement of pharmaceutical, biotech and device products across the Specialty Pharmacy, Specialty Distribution, Retail, Long-Term Care, and Hospital Markets including limited and exclusive distribution models requiring REMS.  Additionally, Dean leads the D2 efforts in working with companies addressing Managed Care and Government payer market access issues. 
    Related Searches
    • quality
    • biotech
    • prescription
    • Development
    Suggested For You
    Pharma Manufacturing: Methods for Real-Time Microbiology Pharma Manufacturing: Methods for Real-Time Microbiology
    Catalent, Acura Enter Clinical Manufacturing Pact Catalent, Acura Enter Clinical Manufacturing Pact
    Leveraging Machine Learning and AI in Clinical Research Leveraging Machine Learning and AI in Clinical Research
    Growth in Biologics and Maintaining Patient Satisfaction  Growth in Biologics and Maintaining Patient Satisfaction
    Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved
    La Jolla Pharma Receives Orphan Designation for Malaria Treatment La Jolla Pharma Receives Orphan Designation for Malaria Treatment
    17	Takeda 17 Takeda
    08	GlaxoSmithKline 08 GlaxoSmithKline
    Hoth Signs Contract Service Pacts for BioLexa Hoth Signs Contract Service Pacts for BioLexa
    Otsuka Chemical Enters API Business Otsuka Chemical Enters API Business
    Serialization and the Rest of Us Serialization and the Rest of Us
    Camargo to Acquire InSymbiosis Camargo to Acquire InSymbiosis
    Alector, Lonza Partner for Mfg. of Neurodegeneration Therapies Alector, Lonza Partner for Mfg. of Neurodegeneration Therapies
    Ology Wins Two DoD Awards Ology Wins Two DoD Awards
    Bosch Packaging Technology Hosts Pharmatag 2019 Bosch Packaging Technology Hosts Pharmatag 2019

    Related Expert's Opinion

    • Solid Dosage/Creams/Ointments | Solid Dosage/Semi-solids
      PharmParts – This Makes Sense!

      PharmParts – This Makes Sense!

      5 reasons to consider purchasing secondhand parts.
      Justin Kadis, Business Development, Federal Equipment 04.06.21

    • Cold Chain Management
      Cold-Chain Handling Is Not Just a COVID Vaccine Challenge

      Cold-Chain Handling Is Not Just a COVID Vaccine Challenge

      More robust solutions for single-use cold-chain containers made with polytetrafluoroethylene fluoropolymers may be less susceptible to failure and breakage.
      Joe Cintavey, Gore PharmBIO 03.30.21

    • cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
      Fast Track Automation in Pharmaceutical Manufacturing

      Fast Track Automation in Pharmaceutical Manufacturing

      Drug manufacturers turn to advanced automation technologies and project execution methodologies to reduce time, cost and risk
      Steve Zarichniak, Technical Solutions Consultant, Honeywell Process Solutions 03.25.21


    • Clinical Trials | Drug Development
      Regulatory Practices in a Post-Pandemic World

      Regulatory Practices in a Post-Pandemic World

      Envisioning the new normal for clinical development.
      Dr. Ronan Brown, SVP and Head of Integrated Global Compliance, IQVIA 03.22.21

    • Clinical Trials | Information Technology
      The Evolution of Clinical Research Technology to Support Remote Collaboration

      The Evolution of Clinical Research Technology to Support Remote Collaboration

      Pioneering change with technology advancements that yield high reward with tolerable risk.
      Angela Gill Nelms, COO for Florence Healthcare 03.11.21

    • cGMP Manufacture | Process Development | Scale-up/Technology Transfer
      Process Intensification: Understanding the Optimal Way to Maximize Productivity

      Process Intensification: Understanding the Optimal Way to Maximize Productivity

      Overcoming challenges of implementation and achieving increased volume, reduced timelines, decreased footprint, lower cost of goods, and increased flexibility.
      Priyanka Gupta, Head of Market Entry Strategy for Protein Based Therapeutics, Sartorius 03.09.21


    • Clinical Trials | Information Technology
      Data Management Trends

      Data Management Trends

      Pandemic-fueled patient centricity is creating new challenges and opportunities for data management teams.
      Deepu Joseph, Global Head & VP of Clinical Data Management 03.05.21

    • Clinical Trials | Information Technology
      Top 5 Things to Know Before Selecting Clinical Trial Technology

      Top 5 Things to Know Before Selecting Clinical Trial Technology

      Look for a future-proof model, innovative vendors - not cutting-edge technology, and focus on user-centered design and interoperability.
      Andres Garcia, Co-founder and CTO Florence 02.08.21

    • Clinical Trials
      The Future of Clinical Trials Series: Part II

      The Future of Clinical Trials Series: Part II

      Greater awareness will ensure diversity is no longer an afterthought and patients will be at the center of every aspect of clinical research.
      Jena Daniels, Rasmus Hogreffe, Ingrid Oakley-Girvan, Dr. Michelle Longmire, Medable 01.26.21


    • Clinical Trials
      The Future of Clinical Trials Series: Part I

      The Future of Clinical Trials Series: Part I

      What will 2021 have in store for an industry in flux?
      Alison Holland, Head of Decentralized Trials, Medable, Maria Fotiu, Executive Vice President of Decentralized Solutions, Syneos Health 01.19.21

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21


    • Drug Development | Industry News | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups 01.05.21

    • Cold Chain Management | Logistics
      COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

      COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

      How the air cargo logistics community is embracing technology to close critical gaps in the cold chain.
      Chris Jones, EVP, Marketing and Services, Descartes 12.15.20

    • Clinical Trials | Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown, SVP of Integrated Technology & Compliance, and Joe Rymsza, VP, Global PV & Regulatory Technology Solutions, IQVIA 12.14.20

    Trending
    • Jubilant, Novavax Enter COVID-19 Vaccine Partnership
    • Pfizer, BioNTech Expand COVID-19 Vaccine Agreement With EU
    • Resilience Acquires Ology Bioservices
    • Ensuring Pharma Manufacturing Quality
    • Sartorius Expands In The UK
    Breaking News
    • Resilience Acquires Ology Bioservices
    • RDIF, Hualan Ink COVID-19 Vaccine Deal
    • Kintor, Visum Enter COVID-19 Manufacturing Partnership
    • Pfizer, BioNTech Expand COVID-19 Vaccine Agreement with EU
    • Evotec Enters Master Service Agreement with Kazia Therapeutics
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Review Concludes That Refined Grains Have a Place in Healthy Eating Patterns
    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    Coatings World

    Latest Breaking News From Coatings World

    SOS '21 Call For Papers
    ICP Acquiring Choice Adhesives
    PPG Brand Olympic Stains Announces 1st Ever 2021 Stain Color of the Year
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs Canon Medical's One-Beat Spectral Cardiac CT
    NeuroLogica Debuts Next-Generation SmartMSU with OmniTom Elite
    IZI Medical Products Launches Fully Automatic Quick-Core Auto Biopsy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Resilience Acquires Ology Bioservices
    RDIF, Hualan Ink COVID-19 Vaccine Deal
    Kintor, Visum Enter COVID-19 Manufacturing Partnership
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    2021 Perfumed Plume Awards Announces Finalists
    Bésame Cosmetics Unveils Marilyn Monroe Collection
    Procos Opens U.S. Office
    Happi

    Latest Breaking News From Happi

    Hair Luxury Company Expands Availability of Its Vegan Beauty to Walmart Online
    ACI Appoints Director, State Government Affairs
    Jergens Launches Mother’s Day Campaign
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Sakata INX and INX International continue sustainability efforts
    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Andritz to Supply Elliptical Cylinder Pre-Needler in France
    Ahlstrom-Munksjö to be Delisted from Nasdaq Stockholm
    Radienz Living Introduces Sustainable Products
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    AgNovos Healthcare's AGN1 LOEP SV Kit Obtains IDE
    First Surgeries Completed with Globus Medical's CREO ONE Robotic Screw
    BioMagnetic Sciences Names President and CEO
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    SEMI, Center for Automotive Research Collaborate
    Zebra Technologies Introduces New Alliance Track for PartnerConnect Channel Program
    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login